The ML-10 molecule is an imaging product which is a molecular tracer, injected into the body with a standard syringe. The tracer binds to cells undergoing apoptosis and is designated for the diagnosis of diseases characterized with apoptosis, or for the assessment of effectiveness of treatment in such diseases. The product was developed by the Company until 2013, and its further development was halted following the results of the Phase II clinical trial for the imaging of apoptosis in brain metastases treated with radiation; results which did not meet the primary endpoints of the trial.